López-Veloso, A.C. (A.C.)

Filtering

20211

Settings

Author search.filters.isAuthorOfPublication.e022f394-7702-4165-b5d6-b52017b4ff63

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
    (Elsevier, 2021) Caronna, E. (Edoardo); Gallardo, V.J. (Víctor José); Alpuente, A. (A.); Torres-Ferrús, M. (M.); Morollón-Sánchez-Mateo, N. (Noemí); Viguera-Romero, J. (J.); López-Veloso, A.C. (A.C.); López-Bravo, A. (Alba); Gago-Veiga, A.B. (A.B); Irimia, P. (Pablo); Porta-Etessam, J. (J.); Santos-Lasaosa, S. (Sonia); Pozo-Rosich, P. (Patricia)
    Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.